Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

导出 LinkOut

翻译打印收藏纠错

作者： Daniel H,Deck ^[1] ; Jennifer M,Jordan ^[2] ; Thomas L,Holland ^[3] ; Weihong,Fan ^[4] ; Matthew A,Wikler ^[4] ; Katherine A,Sulham ^[4] ; G,Ralph Corey ^[3]

作者单位： The Medicines Company, Parsippany, NJ, USA. Daniel.Deck@THEMEDCO.com. ^[1] The Medicines Company, Parsippany, NJ, USA. Jennifer.jordan@themedco.com. ^[2] Duke University Hospital, Durham, NC, USA. ^[3] The Medicines Company, Parsippany, NJ, USA. ^[4]

关键词 Acute bacterial skin and skin structure infections (ABSSSI)Eron classification Oritavancin Outpatient

DOI 10.1007/s40121-016-0119-9

PMID 27370913

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览30

Infectious diseases and therapy

2016年5卷3期

353-61页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Infectious diseases and therapy

相似文献

Infectious diseases and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Infectious diseases and therapy

相似文献

Infectious diseases and therapy

相关期刊

检索历史清除